Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

A feasibility study of the intraductal administration of chemotherapy.

Love SM, Zhang W, Gordon EJ, Rao J, Yang H, Li J, Zhang B, Wang X, Chen G, Zhang B.

Cancer Prev Res (Phila). 2013 Jan;6(1):51-8. doi: 10.1158/1940-6207.CAPR-12-0228. Epub 2012 Nov 20. Erratum in: Cancer Prev Res (Phila). 2013 May;6(5):506.

PMID:
23169924
[PubMed - indexed for MEDLINE]
2.

Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.

Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, Tsangaris TN, Sukumar S.

Sci Transl Med. 2011 Oct 26;3(106):106ra108. doi: 10.1126/scitranslmed.3002368.

PMID:
22030751
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Breast-duct endoscopy to study stages of cancerous breast disease.

Love SM, Barsky SH.

Lancet. 1996 Oct 12;348(9033):997-9.

PMID:
8855857
[PubMed - indexed for MEDLINE]
4.
5.

Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.

Qi M, Li JF, Xie YT, Lu AP, Lin BY, Ouyang T.

Breast Cancer Res Treat. 2010 Aug;123(1):197-202. doi: 10.1007/s10549-010-1000-2. Epub 2010 Jun 26.

PMID:
20582466
[PubMed - indexed for MEDLINE]
6.

A feasibility study of neo-adjuvant low-dose fractionated radiotherapy with two different concurrent anthracycline-docetaxel schedules in stage IIA/B-IIIA breast cancer.

Nardone L, Valentini V, Marino L, De Santis MC, Terribile D, Franceschini G, Balducci M, Mantini G, Mattiucci G, Mulè A, Belli P, Masetti R.

Tumori. 2012 Jan-Feb;98(1):79-85. doi: 10.1700/1053.11503.

PMID:
22495705
[PubMed - indexed for MEDLINE]
8.

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.

Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators.

BMC Cancer. 2006 Aug 1;6:202.

PMID:
16882344
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
[PubMed - indexed for MEDLINE]
11.

Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.

Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P, Markopoulos C.

Ann Oncol. 2002 Nov;13(11):1737-42.

PMID:
12419745
[PubMed - indexed for MEDLINE]
Free Article
12.

Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.

Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marenghi C, Curigliano G, Radice D, Adamoli L, Nolè F.

Breast. 2010 Feb;19(1):33-7. doi: 10.1016/j.breast.2009.10.003. Epub 2009 Nov 1.

PMID:
19884008
[PubMed - indexed for MEDLINE]
13.

Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.

Ellerbroek N, Martino S, Mautner B, Tao ML, Rose C, Botnick L.

Breast J. 2003 Mar-Apr;9(2):74-8.

PMID:
12603378
[PubMed - indexed for MEDLINE]
14.

[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].

Zheng H, Gao YN, Jiang GQ, Gao M, Wang W, Yan X.

Zhonghua Fu Chan Ke Za Zhi. 2008 Nov;43(11):839-42. Chinese.

PMID:
19087568
[PubMed - indexed for MEDLINE]
15.

[Drug concentration in axillary lymph nodes of patients with breast cancer after lymphatic chemotherapy].

Chen JH, Yang YM, Li KZ, Ling R, Yao Q, Yang H.

Ai Zheng. 2005 Apr;24(4):494-7. Chinese.

PMID:
15820077
[PubMed - indexed for MEDLINE]
16.

A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.

Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.

Cancer Chemother Pharmacol. 2008 Apr;61(5):847-53. Epub 2007 Jul 4.

PMID:
17609947
[PubMed - indexed for MEDLINE]
17.

Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.

García-Mata J, García-Palomo A, Calvo L, Mel R, Cruz JJ, Ramos M.

Clin Transl Oncol. 2008 Nov;10(11):739-44.

PMID:
19015070
[PubMed - indexed for MEDLINE]
18.

Pattern of distribution of intraductal and infiltrating ductal carcinoma: a three-dimensional study using serial coronal giant sections of the breast.

Mai KT, Yazdi HM, Burns BF, Perkins DG.

Hum Pathol. 2000 Apr;31(4):464-74.

PMID:
10821494
[PubMed - indexed for MEDLINE]
19.

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F.

J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011 Aug 15.

PMID:
21844495
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.

Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN.

Int J Clin Oncol. 2010 Aug;15(4):390-8. doi: 10.1007/s10147-010-0073-6. Epub 2010 Apr 20.

PMID:
20405155
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk